Segment Information (Tables)

6 Months Ended

Dec. 31, 2021

Segment Reporting [Abstract]

Disaggregation of Revenue [Table Text Block]

	Three Months Ended December 31,
(in millions)	2021		2020
Pharmaceutical Distribution and Specialty Solutions (1) (2)	$	41,164	$	37,040
Nuclear and Precision Health Solutions	211		196
Pharmaceutical segment revenue	41,375		37,236
Medical distribution and products (3)	3,446		3,729
Cardinal Health at-Home Solutions	639		581
Medical segment revenue	4,085		4,310
Total segment revenue	45,460		41,546
Corporate (4)	(3)		(5)
Total revenue	$	45,457	$	41,541

	Six Months Ended December 31,
(in millions)	2021		2020
Pharmaceutical Distribution and Specialty Solutions (1) (2)	$	80,778	$	71,956
Nuclear and Precision Health Solutions	419		392
Pharmaceutical segment revenue	81,197		72,348
Medical distribution and products (3)	7,013		7,167
Cardinal Health at-Home Solutions	1,221		1,100
Medical segment revenue	8,234		8,267
Total segment revenue	89,431		80,615
Corporate (4)	(6)		(9)
Total revenue	$	89,425	$	80,606

(1)Products and services offered by our Specialty Solutions division are referred to as “specialty pharmaceutical products and services."

(2)Comprised of all Pharmaceutical segment businesses except for Nuclear and Precision Health Solutions division.

(3)Comprised of all Medical segment businesses except for Cardinal Health at-Home Solutions division.

(4)Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.

Revenue from External Customers by Geographic Areas [Table Text Block]

The following tables present revenue by geographic area:

	Three Months Ended December 31,
(in millions)	2021		2020
United States	$	44,382	$	40,360
International	1,078		1,186
Total segment revenue	45,460		41,546
Corporate (1)	(3)		(5)
Total revenue	$	45,457	$	41,541

	Six Months Ended December 31,
(in millions)	2021		2020
United States	$	87,223	$	78,336
International	2,208		2,279
Total segment revenue	89,431		80,615
Corporate (1)	(6)		(9)
Total revenue	$	89,425	$	80,606

(1)Corporate revenue consists of the elimination of inter-segment revenue and other revenue not allocated to the segments.

Segment Profit by Reportable Segment

The following tables present segment profit by reportable segment and Corporate:

	Three Months Ended December 31,
(in millions)	2021		2020
Pharmaceutical (1)	$	426	$	413
Medical	50		236
Total segment profit	476		649
Corporate	(1,426)		(188)
Total operating earnings/(loss)	$	(950)	$	461

	Six Months Ended December 31,
(in millions)	2021		2020
Pharmaceutical (1)	$	832	$	815
Medical	173		466
Total segment profit	1,005		1,281
Corporate	(1,540)		(1,444)
Total operating loss	$	(535)	$	(163)

(1)Pharmaceutical segment profit during the three and six months ended December 31, 2021 was positively impacted by a $16 million judgment for lost profits related to an ordinary course intellectual property rights claim.

Assets by Reportable Segment

The following table presents total assets for each reportable segment and Corporate at:

(in millions)	December 31, 2021		June 30, 2021
Pharmaceutical	$	24,427	$	23,624
Medical (1) (2)	12,737		15,408
Corporate	6,516		5,421
Total assets	$	43,680	$	44,453

(1)Assets of $1.1 billion classified as held for sale related to the Cordis divestiture were included within Medical at June 30, 2021.

(2)Medical reflects a $1.3 billion goodwill impairment charge recorded in connection with the interim goodwill impairment testing for the Medical Unit at December 31, 2021.